Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NH- NantHealth Points To The Future Of Healthcare
$NH getting in buying range
NantHealth Inc (NH)
4.12 ? -0.18 (-4.19%)
Volume: 701,218 @06/29/20 6:52:49 PM EDT
Bid Ask Day's Range
3.87 4.11 3.68 - 4.24
NH Detailed Quote
$NH it appears to be very undervalue !!!!!
re;
Dang I should have held.. $NH
Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470
Please do your own DD...All my posts are my opinion only!
Dang I should have held...$NH
$NH News: NantHealth Presented Clinical Data on Immunotherapy, Molecularly Targeted Agents & Tumor Biology at the American Society of C... 06/18/2020 04:00:00 PM
NH News: NantHealth to Exhibit at Virtual America’s Health Insurance Plans (AHIP) Institute & Expo 2020 with Webinars to Follow 06/16/2020 11:24:00 AM
$NH News: Specialized Disclosure Report (sd) 05/29/2020 04:03:45 PM
NH News: Statement of Changes in Beneficial Ownership (4) 05/26/2020 05:19:55 PM
NH News: Statement of Changes in Beneficial Ownership (4) 05/26/2020 05:17:30 PM
$NANT reading
$NH "announced its partnership with The Health Plan, a clinically driven, technology-enhanced and customer-focused health maintenance organization,
to increase operating efficiency, lower costs and improve provider satisfaction via the full suite of NaviNet® Open Multi-Payer Portal applications."
NantHealth Inc (NH)
4.79 ? 0.84 (21.27%)
Volume: 1,730,588 @06/24/20 2:54:40 PM EDT
Bid Ask Day's Range
4.79 4.83 3.95 - 4.99
NH Detailed Quote
* * $NH Video Chart 06-15-2020 * *
Link to Video - click here to watch the technical chart video
$NH Dr. Soon Baby!
Please read the last 2 PR's
When was this announced?
$NH "announced its partnership with The Health Plan, a clinically driven, technology-enhanced and customer-focused health maintenance organization, to increase operating efficiency, lower costs and improve provider satisfaction via the full suite of NaviNet® Open Multi-Payer Portal applications."
I wouldn't be surprised to see $3.5/4 by the EOW $NH
$NH Closed above the 52Wk High Yesterday. With PR being released AH yesterday, looking for continuation push to 3$ or higher.
Nice move today. At one time,
it was up 100% today. That $2.75 price will come back. This is not just a virus play. This is bigger than that. Fortunately, I was able to get in early and big on Friday. Not thinking about taking profits yet. Going to wait for the big buying.
Unfortunately, it cannot even sustain half of the gains it scored today. Gonna go south from here.
* * $NH Video Chart 01-28-2020 * *
Link to Video - click here to watch the technical chart video
Fun trading this today. Wish I had held to near the top, though.
NantHealth & NantOmics Reveal a Novel AI Based Machine-Learning Digital Pathology Software for Lung Cancer by Identifying Tum...
NantHealth (NASDAQ:NH)
Intraday Stock Chart
Today : Tuesday 28 January 2020
Derived from deep-learning models, the findings demonstrate novel AI methods of identifying tumor-infiltrating lymphocytes (TILs) in lung cancers
NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis, today presented a novel artificial intelligence platform for aiding pathologists in image-based lung cancer subtyping at the Society for Imaging Science and Technology’s International Symposium on Electronic Imaging 2020. This novel machine vision software platform accurately subtypes lung cancer pathology and achieves high concordance with analysis performed by trained medical pathologists.
An initial report of the AI technology was presented at the Sixth American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC) International Joint Conference. The study entitled, “Tumor-infiltrating lymphocytes (TILs) found elevated in lung adenocarcinomas (LUAD) using automated digital pathology masks derived from deep-learning models” concluded that despite lower overall TMB (tumor mutation burden) and lymphocyte levels, there exists a subset of lung cancers with very high infiltrating lymphocyte counts.
Derived from deep-learning models, together, the findings demonstrate a novel AI-based method for subtyping lung cancer pathologies which impacts treatment options for patients and improved methods of identifying tumor infiltrating white cells found elevated in lung cancer.
“Accurately identifying and quantifying tumor-infiltrating white cells is extremely important for prognosis and treatment decisions in this era of personalized medicine, yet it currently requires manual review of whole slide images by medically trained pathologists, and incurs significant delays and cost,” explains Dr. Patrick Soon-Shiong, MD, Chairman and CEO of NantHealth. “Our goal was to develop a scalable remote cloud-based diagnostic imaging system, a NORAD of pathology diagnosis so to speak. To accomplish this, machine vision of digitally transmitted images of tumor tissue would facilitate a scalable cloud-based infrastructure, with an image patch-based, automated system to classify cancers by their immune status.”
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, which is further classified as 40 percent adenocarcinoma (Adeno), 30 percent squamous cell carcinoma (Squamous) and the remainder, large cell carcinoma1. As analyses show that lung adenocarcinomas (LUAD) receive slightly more survival benefit from anti-PD1 therapy than squamous-cell lung carcinomas (LUSC), which have a higher TMB, a team of researchers explored whether lymphocyte distribution in the tumor microenvironment may give a rational explanation for the different responses to immuno-oncology agents independent of TMB.
“By focusing on classifying regions detected as tumorous, we achieved identification of adenocarcinomas versus squamous cell carcinomas in non-small-cell lung cancers with an approximate accuracy rate of 86 percent,” explained Soon-Shiong. “With highly accurate tumor-region and lymphocyte detection, oncologists may better treat their patients with adeno versus squamous-based therapies and the use of immunotherapies may result in better outcomes.”
Study Design:
The system was trained and tested on 876 subtyped NSCLC gigapixel-resolution diagnostic whole slide images (WSI) from 805 patients obtained from The Cancer Genome Atlas (TCGA) sources. Samples were randomly split into training (711 WSIs from 664 patients) and testing (165 WSIs from 141 patients) sets.
Findings show that NantOmics and NantHealth’s fully-automated histopathology subtyping AI method outperforms other algorithms reported in literature for diagnostic WSIs. The system also generated maps of (tumor) regions-of-interest within WSIs, providing novel spatial information on tumor organization.
Details of the oral presentation at the IS&T International Symposium on Electronic Imaging 2020 outlined below:
Title: “Pathology image-based lung cancer subtyping using deep-learning features and cell-density maps”
Authors: Mustafa I. Jaber, Christopher W. Szeto, Bing Song, Liudmila Beziaeva, Stephen Benz, Patrick Soon-Shiong, and Shahrooz Rabizadeh
Session and Number: Image Processing: Algorithms and Systems XVIII (IPAS-064)
Location: Hyatt Regency San Francisco Airport, Burlingame, CA
Date and Time: January 27, 2020 at 4:10 PM
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers molecular diagnostic capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About NantHealth:
NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.
Forward-Looking Statements: NantHealth
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.
1 M Jaber, C. Szeto, B. Song, L. Beziaeva, S. Benz, P. Soon-Shiong and S. Rabizadeh, “Pathology image-based lung cancer subtyping using deep-learning features and cell-density maps,” To be published as part of the proceedings from the IS&T International Symposium on Electronic Imaging 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200127005739/en/
NANT
Jen Hodson
Jen@nant.com
562-397-3639
The Health Plan Serving Over 200,000 Covered Lives Selects NantHealth’s NaviNet® Open to Drive Provider Engagement Strategy
NantHealth (NASDAQ:NH)
Intraday Stock Chart
Today : Tuesday 28 January 2020
Click Here for more NantHealth Charts.
New Partnership to Enable Cost Savings and Rapid ROI Across the Continuum of Care
NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced its partnership with The Health Plan, a clinically driven, technology-enhanced and customer-focused health maintenance organization, to increase operating efficiency, lower costs and improve provider satisfaction via the full suite of NaviNet® Open Multi-Payer Portal applications.
The Health Plan is one of the largest locally managed care organizations in West Virginia and Ohio, serving over 200,000 covered lives, and is committed to providing high quality, comprehensive and cost-effective healthcare to members.
NaviNet Open is a leading payor-provider collaboration platform, enhancing communication between health plans and providers to increase operating efficiency, lower costs, improve provider satisfaction and enable expansion. As organizations develop more value-based product lines to support the transition to value-based care, provider alignment and actionable data prior to care delivery becomes critical. To enable these capabilities, health plans and providers need a flexible, extensible infrastructure that fosters collaboration and encourages interoperability. NaviNet Open delivers vital administrative and clinical information to providers in real-time, so they can quickly and easily communicate across multiple health plans.
“NantHealth’s NaviNet Open delivers an easy-to-use full-service application capable of reducing customer service calls and manual processes,” said Jason Landers, Senior Vice President Provider Delivery Services, The Health Plan. “Considering that 85% of our provider networks are active NaviNet Open users, we’ll immediately have the ability to securely and quickly obtain both clinical and administrative functions, with minimal provider adoption effort. This alone is a huge differentiator for us, and we’re projecting a positive ROI in the first year of usage.”
Under terms of the partnership, NaviNet Open will drive The Health Plan’s provider engagement strategy through the NaviNet Open portal, comprised of Eligibility and Benefits, Claims Status Inquiry, Claims Management, Authorizations, Referrals and Document Exchange. The portal will enhance communications by building trust, boosting provider satisfaction, and more closely aligning to value-based outcomes.
“We’re excited to be working in partnership with The Health Plan to enable a direct connection with their provider networks with an outcome of impressive cost savings, ongoing support, product improvements, and enhanced communications,” said Mark Mozley, Senior Vice President, Global Sales & Marketing, NantHealth. “NaviNet Open will continue to drive towards The Health Plan’s overarching goals to achieve instant ROI with decreased administrative costs and an improved provider network collaboration.”
About NantHealth:
NantHealth, a member of the NantWorks ecosystem of companies, provides leading solutions across the continuum of care for physicians, payors, patients and biopharmaceutical organizations. NantHealth enables the use of cutting-edge data and technology toward the goals of empowering clinical decision support and improving patient outcomes. NantHealth’s comprehensive product portfolio combines the latest technology in payor/provider platforms that exchange information in near-real time (NaviNet and Eviti), connected care solutions that deliver medical device interoperability (DCX device connectivity platform and VCX patient vitals software) and molecular profiling services that combine comprehensive DNA & RNA tumor-normal profiling with pharmacogenomics analysis (GPS Cancer®). For more information, please visit www.nanthealth.com or follow us on Twitter, Facebook and LinkedIn.
About The Health Plan:
The Health Plan (www.healthplan.org), a not-for-profit, West Virginia-based organization that employs over 550 people and insures over 200,000 individuals across the country, is a clinically driven, technology-enhanced, and customer-focused health maintenance organization that manages and improves the health and well-being of its members. Established in 1979, the West Virginia-based company, with offices in Wheeling, Charleston and Morgantown, West Virginia and Massillon, Ohio offers a complete line of managed care products and services designed to provide health care systems and clients with innovative health care benefits and plans at a reasonable cost across the mid-Atlantic region and nationally.
Forward-Looking Statements: NantHealth
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with, key thought leaders or payers’ key decision makers in order to establish GPS Cancer as a standard of care for patients with cancer; our ability to grow the market for our Systems Infrastructure, and applications; successfully enhancing our Systems Infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with NantOmics; our ability to obtain regulatory approvals; dependence upon senior management; the need to comply with and meet applicable laws and regulations; unexpected adverse events; clinical adoption and market acceptance of GPS Cancer; and anticipated cost savings. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our reports filed with the Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005031/en/
NANT
Jen Hodson
Jen@nant.com
562-397-3639
Masimo to Acquire Connected Care Business from NantHealth
Irvine and Culver City, California -- January 14, 2020 - Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies, and NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced the signing of a definitive agreement under which Masimo will acquire the Connected Care assets from NantHealth, Inc. for a $47.25 million upfront cash payment. NantHealth’s Connected Care solutions provide medical device interoperability to hospitals and health systems. The portfolio includes DCX™ device connectivity (formerly known as DeviceConX™), VCX™ patient vitals software (formerly known as VitalsConX™), HBox® connectivity hub, and Shuttle interface cable.
The acquisition supports Masimo’s goal to help hospitals improve the continuum of great care through hospital automation, connectivity, and innovative noninvasive monitoring technologies. The Connected Care franchise is an established leader in providing connectivity solutions to hospitals, enabling streamlined collection and storage of medical device data through a vendor-agnostic platform into the EHR or other clinical information systems.
“One of the strategic priorities for Masimo is, through our Hospital Automation solutions, to reduce clinician cognitive overload and reduce errors of omission. Through connectivity, predictive algorithms, and decision support, we hope to improve the continuum of great care. The connectivity assets we are acquiring are completely in line with our mission as they will help accelerate our internal growth initiatives in this area,” said Joe Kiani, Founder, Chairman, and CEO of Masimo. “Not only does Connected Care immediately increase our customer footprint but also provides us with products which complement our current portfolio. As a result, we are very excited to welcome the Connected Care’s talented team to Masimo and look forward to realizing our vision together.”
Patrick Soon-Shiong, MBBCh, MSc, FRCS (C), NantHealth Chief Executive Officer and Chairman of the Board said, “Our decision to sell the Connected Care business enables us to focus on accelerating growth for our NaviNet® and Eviti® SaaS solutions, our data and molecular analytics capabilities, and pursue other strategically aligned goals. We believe Masimo has the best connectivity solutions, and we are delighted to have found the right home for our Connected Care business and our committed team of employees. We are working with Masimo to ensure a smooth transition for our Connected Care customers.”
The transaction is expected to close in the first quarter of 2020, subject to customary closing conditions. Masimo expects to fund the acquisition with existing cash on hand. The estimated financial impact of the transaction is included in Masimo’s full-year 2020 financial guidance, which is being issued in a separate press release today.
$NH: I see people on Discord tracking $NH
Its gonna get lots more flow now
GO $NH
$NH: $3 break would be beautiful.
This is gonna go NUTS just like $NK did.
Don't be surprised when Dr.Shoo has this over $10 very shortly.
GO $NH
$NH: $2.58 going..............
I told you at $2.15 entry.
Don't say You weren't told.
Whats My name ?
Only 30% a Day.
Better than returns on your Checking Account.
GO $NH
$NH: Buy $2.15..... And don't look back
Just got you a much better ENTRY !
You just saw what $NK did.
$NH is next
GO $NH
$NH: Another Dr.Patrick-Soon-Shiong production... Now at $2.06
Only now just getting attention.
EASY TRIPLE FROM HERE....... now at $2.006
Patrick Soon-Shiong, MBBCh, MSc, FRCS (C)
Chief Executive Officer and Chairman of the Board
Since the formation of our company in July 2010, Dr. Patrick Soon-Shiong has served as our Chief Executive Officer and as Chairman of our Board of Directors. Dr. Soon-Shiong, a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields. Read full biography.
$NH: Looks great here.... another $NK in the making
Made like Gangbusters on $NK.
I see the same here on $NH
Nice rebound to $8 could come now.
Sitting at $2.15 with more volume building... its rolling.
https://ir.nanthealth.com/static-files/d48b8051-8710-49fb-a4f6-5fab69d8ee6a
GO $NH
* * $NH Video Chart 01-14-2020 * *
Link to Video - click here to watch the technical chart video
nice DD here
Nice info... Good volume Monday!
NantHealth granted US FDA 510(k) approval, this approval was granted on Saturday (11/9) and has yet to be announced publicly.
Thinly traded so be careful.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K190661
* * $NH Video Chart 03-01-2019 * *
Link to Video - click here to watch the technical chart video
I just jumped in here at 1.09.
Moving like a lf but it’s actually quite big
Still holding... sold a 1/3 1,80‘s
Something cooking here
* * $NH Video Chart 09-13-18 * *
Link to Video - click here to watch the technical chart video
Hello, is anyone else watching this??
NH up another double digit % today!
Yet another upside trade into the wkend
......positive trend is cookin' at NH folks!!!
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
153
|
Created
|
05/17/17
|
Type
|
Free
|
Moderators |
9920 Jefferson Boulevard
Culver City, CA 90232
Shs Float | 44.31M |
Debt/Eq | - |
NantHealth and our payer partners have collaborated to provide a list of resources to help our customers care for patients who may be impacted by COVID-19
Health care information is sensitive, personal, and private. In today’s modern landscape of data breaches and database hacks,
patient information is one thing you don’t want falling into the wrong hands.
NantHealth as a whole takes steps to protect patient data at all costs. Accordingly, our NaviNet platform is designed and built to the most rigorous security standards,
then meticulously maintained to prevent new threats as they arise—and endure safe information transfer at all times.
With comprehensive security technology, providers, payers, and patients alike can rest easier knowing their information is safe from prying eyes.
NaviNet deploys advanced security protocols to protect private information, including:
NaviNet does all of this while maintaining—and surpassing—HIPAA compliance guidelines. Putting the security of
patient data first is a requirement of putting patients first—and something to which we are wholly committed.
NaviNet Security Officers are well-trained to keep data secure and protected.
They are your go-to source for managing security practices within each provider practice. Their responsibilities include:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |